MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Caregiver Burden after DBS at GPI or STN for Parkinson’s Disease

    A. Kamath, H. Branstetter, J. Summers, T. Hassell, S. Bick, N. Banerjee, K. Dhima (Nashville, USA)

    Objective: Examine the effects of GPi or STN DBS on caregiver burden for Parkinson's Disease Background: Deep Brain Stimulation (DBS) is a common treatment used…
  • 2025 International Congress

    Long term real-world monitoring supports the superiority of adaptive deep brain stimulation: preliminary data on three patients with Parkinson’s disease

    L. Caffi, R. Habib, L. Borellini, E. Mailland, F. Cogiamanian, M. Arlotti, L. Rossi, S. Bonvegna, C. Palmisano, S. Marceglia, A. Priori, G. Pezzoli, M. Locatelli, IU. Isaias (Würzburg, Germany)

    Objective: Describe the preliminary results of adaptive deep brain stimulation (aDBS) treatment for Parkinson’s disease (PD) and the value of real-world monitoring in defining clinical…
  • 2025 International Congress

    Trends on recruitment and retention in Parkinson’s Disease modification trials

    D. Hengartner, R. Palacio, J. Garinger, A. Lysandropoulos (Durham, USA)

    Objective: To identify the most common causes of participant’s screen failure (SF) and drop-out (DO) in Phase 2 and 3 Disease Modification Therapy (DMT) trials…
  • 2025 International Congress

    A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

    S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)

    Objective: The study evaluates the effectiveness of Combat PD, a mobile app designed to remotely deliver and monitor gamified aerobic exercise in promoting adherence and…
  • 2025 International Congress

    First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants

    L. Smits, Y. Zhang, C. Woodward, S. Aksenov, A. Costa Zaninotto, C. Donnelly, T. Storz, Y. Folami, P. Patel, C. Lubeski, M. Macdougall, K. Kelly, A. Hendricson, S. Korsten, P. Kremer, A. Cacace, I. Conti (Leiden, Netherlands)

    Objective: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses (SAD/MAD) of ARV-102, a PROteolysis TArgeting Chimera (PROTAC) leucine-rich…
  • 2025 International Congress

    Barriers and Facilitators of Adherence to Mediterranean-Ketogenic and MCT-Supplemented Mediterranean Diets in Parkinson’s Disease: A Qualitative Secondary Analysis from a Random-Order Crossover Trial

    K. Tosefsky, Y. Wang, J. Lam, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To assess the barriers and facilitators of dietary adherence among people with Parkinson’s disease (PD) following an 8-week Mediterranean-ketogenic and 8-week MCT-supplemented Mediterranean diet.…
  • 2025 International Congress

    Neural Mechanisms of Intermittent Theta Burst Stimulation for Depressive Symptoms in Parkinson’s Disease: Insights from fNIRS-Based Cortical Activation and Connectivity Dynamics

    Y. Zhang, M. Hou, Z. Liu (Shanghai, China)

    Objective: This study investigated the neural mechanisms underlying the effects of intermittent theta burst stimulation (iTBS) on depressive symptoms in Parkinson’s disease (PD-D) using functional…
  • 2025 International Congress

    CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders

    L. Murphy, J. Fortanet, D. Baird, T. Lehmberg, K. Skerry, M. Broadus (Boston, USA)

    Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…
  • 2025 International Congress

    Coping with Parkinson’s Disease through the Lens of Personality Systems Interactions (PSI) Theory: Two Case Studies

    E. Wünnenberg, N. Baumann (Trier, Germany)

    Objective: This study examines how concepts from motivation and personality research contribute to understanding coping strategies in individuals with Parkinson’s disease (PD). Background: Effective treatment…
  • 2025 International Congress

    Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis

    A. Singh (Prayagraj, India)

    Objective: This study investigated the neuroprotective and neuromodulatory effects of dietary caffeic acid (CA) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian rat model Background: Parkinson’s disease (PD)…
  • « Previous Page
  • 1
  • …
  • 135
  • 136
  • 137
  • 138
  • 139
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley